Table 2.
Currently active companies working on miRNA-based therapeutics
| Companies | Product | Targeted miR | Disease type | Development phase | Reference |
|---|---|---|---|---|---|
| Roche/Santaris | Miravirsen | miR-122 | HCV | Phase 2 | roche.com |
| Regulus Therapeutics | RG-101 RG-012 RG-125 |
miR-122 miR-21 miR-103/107 |
HCV Alport syndrome NASH |
Phase 2 (hold) Phase 1 Phase 1 |
regulusrx.com |
| MiRagen Therapeutics | MRG-201 MRG-106 MRG-107 MRG-110 |
miR-29b miR-155 miR-155 miR-92 |
Fibrosis Lymphoma and leukemia ALS Ischemia |
Phase 2 Phase 1 and Phase 2 Pre-Clinical Phase 1 |
miragentherapeutics.com |
| ENGeneIC | Mesomir | miR-16 | Mesothelioma | Phase 2 | engeneic.com |
| Abivax | ABX464 | miR-124 | IBD | Phase 2 | abivax.com |
| Synlogic | Screening | synlogictx.com | |||
| Opko | Screening | opko.com | |||
| Alnylam Pharmaceuticals | Screening | alnylam.com | |||
| Interna Technologies | Screening | interna-technologies.com | |||
| Mello Biotech | Screening | mellobiotech.com | |||